Nanorobots Clear Arterial Plaque in First-Ever Human Trial

Nanorobots Clear Arterial Plaque in First-Ever Human Trial

On October 15, 2027, Tel Aviv University Medical Center in Israel announced that magnetically guided nanorobots developed by Bionaut Labs had successfully performed a plaque-clearing procedure inside a 67-year-old male patient with coronary artery disease. It marked the first time nanorobots have carried out a therapeutic operation inside the human cardiovascular system.

The patient had a 78% stenosis in the left anterior descending artery; the conventional treatment would have been percutaneous coronary intervention (PCI) with a drug-eluting stent. Instead, the surgical team injected a suspension containing approximately one million nanorobots into the coronary artery via the femoral artery, then used an external magnetic field to guide the robots to the plaque surface. The robots carry cathepsin K on their surface, which activates in the acidic microenvironment of the plaque to selectively degrade the fibrous cap and lipid core.

The procedure lasted approximately four hours. Post-operative angiography showed that the stenosis had dropped from 78% to 31%, with no complications such as vessel perforation or distal embolization. The patient was ambulatory within 24 hours and discharged after 48 hours. Thirty-day follow-up confirmed vessel patency with no signs of restenosis.

"This is a proof of concept, not a mature treatment," emphasized Ron Weinberger, professor of interventional cardiology at Tel Aviv University and the trial's principal investigator. "We have demonstrated that nanorobots can navigate and perform tasks inside human blood vessels, but clinical routine use is still a long way off."

Each nanorobot measures roughly four micrometers in diameter, with a biodegradable polymer shell and a core embedded with superparamagnetic iron oxide nanoparticles that can be precisely manipulated by an external magnetic field. The drug payload of a single robot is minuscule, but the cumulative effect of a million units delivers a therapeutic dose.

On the safety front, the research team acknowledged several potential risks: iron particles released during nanorobot degradation could trigger localized inflammation; magnetic field precision may decrease at complex vascular bifurcations; and the long-term biodistribution and metabolic fate of large volumes of nanomaterials in the bloodstream remain incompletely characterized. "Getting a million micro-devices into the body is one thing—making sure they're all cleared out is one of our biggest challenges," admitted Bionaut Labs co-founder Shlomo Magal.

Bionaut Labs plans to launch a larger Phase I/II trial in 2028, enrolling 30 to 50 patients to further evaluate safety and preliminary efficacy. If the data support it, the company will seek FDA Breakthrough Therapy designation.